DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Epirubicin (Epirubicin) - Side Effect Reports to FDA

 
 



Index of reports > All Cases (264)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Epirubicin all cases. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 264   Next >>

Possible Epirubicin side effects in male

Reported by a physician from United Kingdom on 2012-08-23

Patient: male, weighing 82.0 kg (180.4 pounds)

Reactions: Coronary Artery Disease

Adverse event resulted in: death

Drug(s) suspected as cause:
Avastin
    Dosage: most recent dose: 02/may/2012; most recent dose: 577 mg
    Indication: Gastric Cancer
    Start date: 2012-03-21

Cisplatin
    Dosage: most recent dose: 02/may/2012; most recent dose: 110 mg
    Indication: Gastric Cancer
    Start date: 2012-03-21

Epirubicin
    Dosage: most recent dose: 02/may/2012; most recent dose: 96 mg
    Indication: Gastric Cancer
    Start date: 2012-03-21

Xeloda
    Dosage: most recent dose: 09/may/2012 and most recent dose: 2500 mg daily
    Administration route: Oral
    Indication: Gastric Cancer
    Start date: 2012-03-21



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-08-20

Patient:

Reactions: Abdominal Pain, Vomiting, Hypersensitivity, Nausea, Skin Toxicity, Mucosal Inflammation, Fatigue, Diarrhoea, Hepatotoxicity, Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Breast Cancer

Epirubicin
    Indication: Breast Cancer

Fluorouracil
    Indication: Breast Cancer

Herceptin
    Dosage: loading dose
    Indication: Breast Cancer

Herceptin
    Dosage: maintenance dose

Lapatinib
    Dosage: arm b
    Administration route: Oral
    Indication: Breast Cancer

Lapatinib
    Dosage: arm c
    Administration route: Oral

Paclitaxel
    Indication: Breast Cancer



Possible Epirubicin side effects in 35 year old female

Reported by a physician from Philippines on 2012-08-16

Patient: 35 year old female, weighing 56.2 kg (123.6 pounds)

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: form:vialtotal dose recieved:936 mg
    Start date: 2010-11-04

Docetaxel
    Dosage: form:vialtotal dose recieved:152 mg
    Start date: 2010-09-02

Epirubicin
    Dosage: form:vialtotal dose recieved:140 mg
    Start date: 2010-11-04

Fluorouracil
    Dosage: form:vial
    Start date: 2010-11-04

Trastuzumab
    Dosage: form:vialtotal dose recieved:336 mg
    Start date: 2011-07-21

Trastuzumab
    Dosage: form:vial



Possible Epirubicin side effects in 74 year old male

Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-16

Patient: 74 year old male

Reactions: Hepatitis C

Drug(s) suspected as cause:
Cisplatin
    Dosage: 60 mg/m2, cyclic
    Indication: Hepatic Neoplasm Malignant non-Resectable

Epirubicin
    Dosage: 50 mg/m2, cyclic
    Indication: Hepatic Neoplasm Malignant non-Resectable

Other drugs received by patient: Lipiodol



Possible Epirubicin side effects in 73 year old male

Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-16

Patient: 73 year old male

Reactions: Hepatitis C

Drug(s) suspected as cause:
Cisplatin
    Dosage: 60 mg/m2, cyclic
    Indication: Hepatic Neoplasm Malignant non-Resectable

Epirubicin
    Dosage: 50 mg/m2, cyclic
    Indication: Hepatic Neoplasm Malignant non-Resectable

Other drugs received by patient: Lipiodol



Possible Epirubicin side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-13

Patient: female

Reactions: Oesophageal Candidiasis

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2011-10-14
    End date: 2011-10-14

Cyclophosphamide
    Start date: 2011-09-16

Cyclophosphamide
    Start date: 2011-09-02

Cyclophosphamide
    Start date: 2011-09-30

Epirubicin
    Start date: 2011-09-16

Epirubicin
    Start date: 2011-09-30

Epirubicin
    Start date: 2011-09-02

Epirubicin
    Start date: 2011-10-14
    End date: 2011-10-14

Other drugs received by patient: Neupogen; Taxol; Tamoxifen Citrate; Docetaxel; Acetaminophen and Codeine Phosphate; Docetaxel; Acetaminophen and Codeine Phosphate



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-13

Patient:

Reactions: Dyspnoea, Brain Natriuretic Peptide Increased, Ejection Fraction Decreased, Nail Disorder, Cardiac Failure Congestive, Infusion Related Reaction

Drug(s) suspected as cause:
Adriamycin PFS
    Dosage: 40-60 mg/m2 for fac and 60 mg/m2 for ac
    Indication: Breast Cancer

Cyclophosphamide
    Dosage: 500 mg/m2 for fac regimen and 600 mg/m2 for ac regimen
    Indication: Breast Cancer

Docetaxel
    Indication: Breast Cancer

Doxorubicin Hydrochloride
    Dosage: 40-60 mg/m2 for fac and 60 mg/m2 for ac
    Indication: Breast Cancer

Epirubicin
    Dosage: 75-100 mg/m2
    Indication: Breast Cancer

Fluorouracil
    Indication: Breast Cancer

Paclitaxel
    Indication: Breast Cancer

Trastuzumab
    Dosage: 8 mg/kg followed by maintenance (md) 6 mg/kg every 3 wks or 4 mg/kg followed by 2 mg/kg weekly md
    Indication: Breast Cancer



Possible Epirubicin side effects in

Reported by a consumer/non-health professional from Japan on 2012-08-10

Patient:

Reactions: Injection Site Vasculitis, Injection Site Pain, Injection Site Phlebitis

Drug(s) suspected as cause:
Epirubicin
    Indication: Breast Cancer

Fosaprepitant Dimeglumine
    Dosage: 150 mg, once
    Indication: Prophylaxis of Nausea and Vomiting
    Start date: 2012-02-06
    End date: 2012-02-06

Fosaprepitant Dimeglumine
    Dosage: 150 mg, once
    Start date: 2012-02-27
    End date: 2012-02-27

Fosaprepitant Dimeglumine
    Dosage: 150 mg, once
    Start date: 2012-03-19
    End date: 2012-03-19

Other drugs received by patient: Cyclophosphamide



Possible Epirubicin side effects in 73 year old male

Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-09

Patient: 73 year old male

Reactions: Hepatitis C

Drug(s) suspected as cause:
Cisplatin
    Dosage: 60 mg/m2
    Indication: Hepatic Neoplasm Malignant non-Resectable

Epirubicin
    Dosage: 50 mg/m2
    Indication: Hepatic Neoplasm Malignant non-Resectable

Other drugs received by patient: Lipiodol



Possible Epirubicin side effects in

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-09

Patient:

Reactions: Brain Natriuretic Peptide Increased, Dyspnoea, Ejection Fraction Decreased, Nail Disorder, Cardiac Failure Congestive, Infusion Related Reaction

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 500 mg/m2 for fac regimen and 600 mg/m2 for ac regimen
    Indication: Breast Cancer

Docetaxel
    Indication: Breast Cancer

Doxorubicin Hydrochloride
    Dosage: 40-60 mg/m2 for fac and 60 mg/m2 for ac
    Indication: Breast Cancer

Epirubicin
    Dosage: 75-100 mg/m2
    Indication: Breast Cancer

Fluorouracil
    Indication: Breast Cancer

Paclitaxel
    Indication: Breast Cancer

Trastuzumab
    Dosage: 8 mg/kg followed by maintenance (md) 6 mg/kg every 3 wks or 4 mg/kg followed by 2 mg/kg weekly md
    Indication: Breast Cancer



Possible Epirubicin side effects in 35 year old female

Reported by a physician from Philippines on 2012-08-09

Patient: 35 year old female, weighing 56.2 kg (123.6 pounds)

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: form:vialtotal dose recieved:936 mg
    Start date: 2010-11-04

Docetaxel
    Dosage: form:vialtotal dose recieved:152 mg
    Start date: 2010-09-02

Epirubicin
    Dosage: form:vialtotal dose recieved:140 mg
    Start date: 2010-11-04

Fluorouracil
    Dosage: form:vial
    Start date: 2010-11-04

Trastuzumab
    Dosage: form:vial

Trastuzumab
    Dosage: form:vialtotal dose recieved:336 mg
    Start date: 2011-07-21



Possible Epirubicin side effects in 74 year old male

Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-09

Patient: 74 year old male

Reactions: Hepatitis C

Drug(s) suspected as cause:
Cisplatin
    Dosage: 60 mg/m2
    Indication: Hepatic Neoplasm Malignant non-Resectable

Epirubicin
    Dosage: 50 mg/m2
    Indication: Hepatic Neoplasm Malignant non-Resectable

Other drugs received by patient: Lipiodol



Possible Epirubicin side effects in

Reported by a consumer/non-health professional from Canada on 2012-07-30

Patient:

Reactions: Disease Progression

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Product Used FOR Unknown Indication

Epirubicin
    Indication: Product Used FOR Unknown Indication

Fluorouracil
    Indication: Product Used FOR Unknown Indication

Xeloda
    Indication: Product Used FOR Unknown Indication



Possible Epirubicin side effects in female

Reported by a physician from Netherlands on 2012-07-30

Patient: female, weighing 61.5 kg (135.3 pounds)

Reactions: Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 885 mg, unk
    Indication: Breast Cancer
    Start date: 2011-03-22

Epirubicin
    Dosage: 177 mg, unk
    Indication: Breast Cancer
    Start date: 2011-03-22

Fluorouracil
    Dosage: 885 mg, unk
    Indication: Breast Cancer
    Start date: 2011-03-22

NO Treatment Received
    Dosage: no treatment received
    Indication: Breast Cancer

Other drugs received by patient: Granisetron



Possible Epirubicin side effects in 57 year old female

Reported by a consumer/non-health professional from Spain on 2012-07-27

Patient: 57 year old female

Reactions: Pyrexia, Neutropenia, Hidradenitis, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Docetaxel
    Indication: Breast Cancer
    Start date: 2006-08-23
    End date: 2006-11-02

Epirubicin
    Indication: Breast Cancer
    Start date: 2006-08-23
    End date: 2006-11-02

Other drugs received by patient: Hipoartel; Simvastatin; Ceftazidime; Pantoprazole



Possible Epirubicin side effects in male

Reported by a physician from Poland on 2012-07-24

Patient: male, weighing 77.0 kg (169.4 pounds)

Reactions: Dyspnoea, Pleural Effusion, Palmar-Plantar Erythrodysaesthesia Syndrome, General Physical Health Deterioration, Neutropenia, Polyneuropathy, Disease Progression

Adverse event resulted in: death

Drug(s) suspected as cause:
Capecitabine
    Indication: Metastatic Gastric Cancer
    Start date: 2010-10-27
    End date: 2011-04-06

Epirubicin
    Indication: Metastatic Gastric Cancer
    Start date: 2010-10-27
    End date: 2011-04-06

Oxaliplatin
    Indication: Metastatic Gastric Cancer
    Start date: 2010-10-27
    End date: 2011-04-06



Possible Epirubicin side effects in 58 year old female

Reported by a physician from Taiwan, Province of China on 2012-07-24

Patient: 58 year old female, weighing 57.3 kg (126.1 pounds)

Reactions: Multi-Organ Failure, Pneumonia, Coagulopathy, Central Nervous System Lesion, Acute Respiratory Distress Syndrome, Neutropenia, Acute Respiratory Failure, Renal Failure Acute

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Epirubicin
    Start date: 2010-12-28
    End date: 2010-12-28

Epirubicin
    Indication: Breast Cancer
    Start date: 2010-09-30
    End date: 2010-09-30

Taxotere
    Indication: Breast Cancer
    Start date: 2010-09-30
    End date: 2010-09-30

Taxotere
    Start date: 2010-12-28
    End date: 2010-12-28

Other drugs received by patient: Granocyte



Possible Epirubicin side effects in female

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-07-23

Patient: female

Reactions: Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
    Indication: Breast Cancer
    Start date: 2011-01-05
    End date: 2011-01-05

Cyclophosphamide
    Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
    Indication: Breast Cancer
    Start date: 2011-02-16
    End date: 2011-02-16

Cyclophosphamide
    Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
    Indication: Breast Cancer
    Start date: 2010-12-08
    End date: 2010-12-08

Epirubicin
    Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
    Indication: Breast Cancer
    Start date: 2011-02-16
    End date: 2011-02-16

Epirubicin
    Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
    Indication: Breast Cancer
    Start date: 2010-12-08
    End date: 2010-12-08

Epirubicin
    Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
    Indication: Breast Cancer
    Start date: 2011-01-05
    End date: 2011-01-05

Fluorouracil
    Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
    Indication: Breast Cancer
    Start date: 2011-01-05
    End date: 2011-01-05

Fluorouracil
    Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
    Indication: Breast Cancer
    Start date: 2011-02-16
    End date: 2011-02-16

Fluorouracil
    Dosage: every cycle intravenous, every cycle intravenous, every cycle intravenous
    Indication: Breast Cancer
    Start date: 2010-12-08
    End date: 2010-12-08

Other drugs received by patient: Dexamethasone; Ondansetron



Possible Epirubicin side effects in 48 year old female

Reported by a health professional (non-physician/pharmacist) from Hong Kong on 2012-07-23

Patient: 48 year old female

Reactions: Vomiting, Nausea, Febrile Neutropenia, Oropharyngeal Pain

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 830mg, every cycle; 800mg, every cycle
    Indication: non-Small Cell Lung Cancer
    Start date: 2010-10-27

Cyclophosphamide
    Dosage: 830mg, every cycle; 800mg, every cycle
    Indication: non-Small Cell Lung Cancer
    Start date: 2010-10-06
    End date: 2010-10-06

Epirubicin
    Dosage: 166mg every cycle; 140mg, every cycle
    Indication: non-Small Cell Lung Cancer
    Start date: 2010-10-06
    End date: 2010-10-06

Epirubicin
    Dosage: 166mg every cycle; 140mg, every cycle
    Indication: non-Small Cell Lung Cancer
    Start date: 2010-10-27

Fluorouracil
    Dosage: 830 mg every cycle; 700 mg, every cycle
    Indication: Breast Cancer
    Start date: 2010-10-06

Fluorouracil
    Dosage: 830 mg every cycle; 700 mg, every cycle
    Indication: Breast Cancer
    Start date: 2010-10-27



Possible Epirubicin side effects in female

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-07-23

Patient: female

Reactions: Diarrhoea, Chills, Febrile Neutropenia, Headache

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: every cycle
    Indication: Breast Cancer
    Start date: 2010-12-08
    End date: 2011-01-05

Epirubicin
    Dosage: every cycle
    Indication: Breast Cancer
    Start date: 2010-12-08
    End date: 2011-01-05

Fluorouracil
    Dosage: every cycle
    Indication: Breast Cancer
    Start date: 2010-12-08
    End date: 2011-01-05

Other drugs received by patient: Dexamethasone; Onsia



Possible Epirubicin side effects in female

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-07-23

Patient: female, weighing 61.2 kg (134.6 pounds)

Reactions: Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: see image
    Indication: Breast Cancer
    Start date: 2009-12-02
    End date: 2009-12-02

Cyclophosphamide
    Dosage: see image
    Indication: Breast Cancer
    Start date: 2009-12-30

Epirubicin
    Dosage: see image
    Indication: Breast Cancer
    Start date: 2009-12-30

Epirubicin
    Dosage: see image
    Indication: Breast Cancer
    Start date: 2009-12-02
    End date: 2009-12-02

Fluorouracil
    Dosage: see image
    Indication: Breast Cancer
    Start date: 2009-12-02
    End date: 2009-12-02

Fluorouracil
    Dosage: see image
    Indication: Breast Cancer
    Start date: 2009-12-30



Possible Epirubicin side effects in 65 year old female

Reported by a health professional (non-physician/pharmacist) from Taiwan, Province of China on 2012-07-23

Patient: 65 year old female, weighing 51.8 kg (114.0 pounds)

Reactions: Acinetobacter Infection, Postoperative Wound Infection, Postoperative Wound Complication, Wound Infection Staphylococcal

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: df, every three weeks intravenous, df, every three weeks intravenous
    Start date: 2010-08-07

Cyclophosphamide
    Dosage: df, every three weeks intravenous, df, every three weeks intravenous
    Start date: 2010-09-09

Epirubicin
    Dosage: df, every three weeks intravenous, df, every three weeks intravenous
    Indication: Breast Cancer
    Start date: 2010-09-09

Epirubicin
    Dosage: df, every three weeks intravenous, df, every three weeks intravenous
    Indication: Breast Cancer
    Start date: 2010-08-07
    End date: 2010-08-07

Fluorouracil
    Dosage: df, every three weeks intravenous, df, every three weeks intravenous
    Indication: Breast Cancer
    Start date: 2010-08-07
    End date: 2010-08-07

Fluorouracil
    Dosage: df, every three weeks intravenous, df, every three weeks intravenous
    Indication: Breast Cancer
    Start date: 2010-09-09

Other drugs received by patient: Granisetron; Dexamethasone; Lamivudine; Metoclopramide Hydrochloride



Possible Epirubicin side effects in 63 year old female

Reported by a health professional (non-physician/pharmacist) from Hong Kong on 2012-07-20

Patient: 63 year old female

Reactions: Febrile Neutropenia

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (df; every cycle), (df; dose reduced)
    Indication: Breast Cancer
    Start date: 2010-06-30
    End date: 2010-06-30

Epirubicin
    Dosage: (df; every cycle), (df; dose reduced)
    Indication: Breast Cancer
    Start date: 2010-06-30
    End date: 2010-06-30

Fluorouracil
    Dosage: (df; every cycle), (df; dose reduced)
    Indication: Breast Cancer
    Start date: 2010-06-30
    End date: 2010-06-30



Possible Epirubicin side effects in 58 year old female

Reported by a health professional (non-physician/pharmacist) from Hong Kong on 2012-07-20

Patient: 58 year old female

Reactions: Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (df; every three weeks intravenous drip), (df; dose reduced intravenous drip)
    Indication: Breast Cancer
    Start date: 2010-08-04
    End date: 2010-08-04

Epirubicin
    Dosage: (df; every three weeks intravenous drip), (df; dose reduced)
    Indication: Breast Cancer
    Start date: 2010-08-04
    End date: 2010-08-04

Fluorouracil
    Dosage: (df; every three weeks intravenous drip), (df; dose reduced)
    Indication: Breast Cancer
    Start date: 2010-08-04
    End date: 2010-08-04



Possible Epirubicin side effects in 44 year old female

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-20

Patient: 44 year old female, weighing 55.5 kg (122.1 pounds)

Reactions: Abdominal Pain, Intestinal Ischaemia, Colitis Ischaemic, White Blood Cell Count Decreased, Vomiting, Blood Creatine Phosphokinase Increased, Gastrointestinal Necrosis, Pyrexia, Multi-Organ Failure, Diarrhoea, GAS Gangrene, Heart Rate Increased, Bone Marrow Failure, Neutropenia, Clostridial Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 7 cycles, total 4 courses
    Indication: Breast Cancer
    Start date: 2011-07-22
    End date: 2011-09-22

Epirubicin
    Dosage: 7 cycles, total 4 courses
    Indication: Breast Cancer
    Start date: 2011-07-22
    End date: 2011-09-22

Taxotere
    Dosage: 4 cycles, total 3 courses, dose taken once daily
    Indication: Breast Cancer
    Start date: 2011-10-14
    End date: 2011-11-25

Other drugs received by patient: Leucon; Lorazepam; Decadron Phosphate; Lorazepam; Kytril; Prochlorperazine; Kytril; Cepharanthin; Decadron Phosphate; Marzulene S



Possible Epirubicin side effects in 62 year old female

Reported by a health professional (non-physician/pharmacist) from Hong Kong on 2012-07-20

Patient: 62 year old female

Reactions: Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (df), (df; dose reduced)
    Indication: Breast Cancer
    Start date: 2010-07-23
    End date: 2010-07-23

Epirubicin
    Dosage: (df), (df; dose reduced)
    Indication: Breast Cancer
    Start date: 2010-07-23
    End date: 2010-07-23

Fluorouracil
    Dosage: (df), (df; dose reduced)
    Indication: Breast Cancer
    Start date: 2010-07-23
    End date: 2010-07-23



Possible Epirubicin side effects in 46 year old female

Reported by a health professional (non-physician/pharmacist) from Croatia (Local Name: Hrvatska) on 2012-07-20

Patient: 46 year old female, weighing 60.0 kg (132.0 pounds)

Reactions: Neutropenia, Thrombocytopenia, Leukopenia

Adverse event resulted in: life threatening event

Drug(s) suspected as cause:
Epirubicin
    Start date: 2012-05-17
    End date: 2012-05-18

Epirubicin
    Start date: 2012-05-17
    End date: 2012-05-18

Epirubicin
    Start date: 2012-05-17
    End date: 2012-05-18

Ifosfamide
    Start date: 2012-05-17
    End date: 2012-05-18

Mesna
    Start date: 2012-05-17
    End date: 2012-05-18



Possible Epirubicin side effects in female

Reported by a health professional (non-physician/pharmacist) from Thailand on 2012-07-20

Patient: female

Reactions: Febrile Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: (800 mg; every cycle), (800 mg; every cycle)
    Indication: Breast Cancer
    Start date: 2009-10-29
    End date: 2009-10-29

Cyclophosphamide
    Dosage: (800 mg; every cycle), (800 mg; every cycle)
    Indication: Breast Cancer
    Start date: 2010-01-04
    End date: 2010-01-04

Epirubicin
    Dosage: (150 mg; every cycle), (150 mg; every cycle)
    Indication: Breast Cancer
    Start date: 2010-01-04
    End date: 2010-01-04

Epirubicin
    Dosage: (150 mg; every cycle), (150 mg; every cycle)
    Indication: Breast Cancer
    Start date: 2009-10-29
    End date: 2009-10-29

Fluorouracil
    Dosage: (800 mg; every cycle), (800 mg; every cycle)
    Indication: Breast Cancer
    Start date: 2010-01-04
    End date: 2010-01-04

Fluorouracil
    Dosage: (800 mg; every cycle), (800 mg; every cycle)
    Indication: Breast Cancer
    Start date: 2009-10-29
    End date: 2009-10-29

Other drugs received by patient: Ondansetron; Lenograstim; Dexamethasone



Possible Epirubicin side effects in female

Reported by a health professional (non-physician/pharmacist) from France on 2012-07-09

Patient: female

Reactions: Drug Intolerance, Tongue Neoplasm Malignant Stage Unspecified

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Breast Neoplasm
    Start date: 2011-08-01

Cyclophosphamide
    Dosage: 14 days on 21 days
    Start date: 2011-02-01
    End date: 2011-07-01

Cyclophosphamide
    Start date: 2004-12-03
    End date: 2005-02-02

Doxorubicin HCL
    Dosage: 9 courses
    Indication: Product Used FOR Unknown Indication
    Start date: 2009-02-19
    End date: 2009-11-05

Doxorubicin HCL
    Dosage: 8 courses
    Start date: 2007-11-27
    End date: 2008-06-24

Epirubicin
    Indication: Product Used FOR Unknown Indication
    Start date: 2004-12-03
    End date: 2005-02-02

Fluorouracil
    Indication: Product Used FOR Unknown Indication
    Start date: 2004-12-03
    End date: 2005-02-02

Taxotere
    Indication: Product Used FOR Unknown Indication
    Start date: 2005-03-08
    End date: 2005-04-19

Other drugs received by patient: Aromasin; Navoban; Xeloda; Faslodex; Estracyt; Femara; Arimidex; Navelbine



Possible Epirubicin side effects in 50 year old female

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-02

Patient: 50 year old female

Reactions: Acute Myeloid Leukaemia

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: received eight courses.

Docetaxel
    Dosage: eight courses.

Epirubicin
    Dosage: received eight courses.

Therapeutic Radiopharmaceuticals
    Dosage: received 50 gy of irradiation to conserved breast and supraclavicular fossa



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012